Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.78 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | SELL | P14151 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204392 | 0.88 | MMP2 (1.00) | MMP2G6PDCASP7CASP6SELL | |
| SCHEMBL29547161 | 0.88 | MMP2 (1.00) | MMP2G6PDCASP7CASP6SELL | |
| 2,3-Dihydroxybenzoic Acid SCHEMBL21114367 | 0.88 | SELL (0.70) | MMP2G6PDCASP7CASP6SELL | |
| 2,3-Dihydroxybenzoic Acid SCHEMBL37458 | 0.88 | SELL (0.70) | MMP2G6PDCASP7CASP6SELL | |
| 2,3-Dihydroxybenzoic Acid SCHEMBL29362091 | 0.88 | SELL (0.70) | MMP2G6PDCASP7CASP6SELL | |
| Ammonia Solution, Strong SCHEMBL1224587 | 0.86 | MMP2 (0.96) | MMP2G6PDCASP7CASP6SELL | |
| Hydrochloric Acid SCHEMBL5110306 | 0.86 | MMP2 (0.96) | MMP2G6PDCASP7CASP6SELL | |
| SCHEMBL28118326 | 0.86 | MMP2 (0.96) | MMP2G6PDCASP7CASP6SELL | |
| SCHEMBL27725387 | 0.86 | MMP2 (0.96) | MMP2G6PDCASP7CASP6SELL | |
| 2,3-Dihydroxybenzoic Acid SCHEMBL23062831 | 0.86 | SELL (0.67) | MMP2G6PDCASP7CASP6SELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2011-06-16 | — | — | US | claimed |
| WO-2009111611-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISLET AMYLOID POLYPEPTIDE (IAPP) ACCUMULATION IN DIABETES | PROTEOTECH INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTEOTECH INC. | 2009-09-10 | — | — | US | claimed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | claimed |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9469605-B2 | Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies | PROTAMED, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140288183-A1 | Compounds and Compositions for use a Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8829198-B2 | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies | PROTEOTECH INC (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2328417-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140005240-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTEOTECH, INC. | 2014-01-02 | — | — | US | disclosed |
| US-8455687-B2 | Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies | PROTEOTECH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2328417-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010039308-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009111611-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISLET AMYLOID POLYPEPTIDE (IAPP) ACCUMULATION IN DIABETES | PROTEOTECH INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | PROTEOTECH INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | PROTAMED, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288183-A1 | Compounds and Compositions for use a Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | MMP2 3826/4885G6PD 3580/4885CASP7 1816/4885 |
| US-20110144124-A1 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | MMP2 3867/4885G6PD 3579/4885CASP7 1837/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | MMP2 3867/4885G6PD 3579/4885CASP7 1837/4885 |
| US-20140005240-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | MMP2 3867/4885G6PD 3579/4885CASP7 1837/4885 |
| US-20090111863-A1 | Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | SNCA, PARK7, APP | MMP2 2788/4885G6PD 1731/4885CASP7 1686/4885 |
| US-20090227647-A1 | Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes | IAPP, AMY2A, IDE | MMP2 1022/4885G6PD 2119/4885CASP7 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.